New dialysis gadget aims to clean blood better and boost life quality

NCT ID NCT07656168

Recruiting now Disease control Sponsor: China-Japan Friendship Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a special cartridge (pHA130) added to regular dialysis to remove toxins that standard dialysis misses. One hundred adults with kidney failure on maintenance dialysis will be split into two groups: one gets the new cartridge once a week plus standard dialysis twice a week, the other gets standard dialysis three times a week. The goal is to see if the new approach lowers certain toxins and improves quality of life over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pHA130 hemoadsorption cartridge (a device used during dialysis to remove more toxins)
What this could lead to: If it works, this could offer a better way to filter blood during dialysis, potentially reducing heart problems and improving daily life for people with kidney failure.
What could go wrong: This is a small, early-stage trial with only 100 participants. The new cartridge may not work better than standard dialysis, and there could be side effects like allergic reactions or bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESRD (END STAGE RENAL DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESRD (END STAGE RENAL DISEASE) MAINTENANCE HEMODIALYSIS

Contacts and locations

Locations

China-Japan Friendship Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.